(CercleFinance.com) – GenSight Biologics reported on Friday evening a cash position of 13.9 million as of September 30, compared to 24.1 million euros as of June 30.
In a press release, the biopharmaceutical company – which mentions a sufficient financing horizon until the beginning of 2023 – indicates that it has studied several financing options in recent months.
The company now specifies that it is finalizing the obtaining of financing presented as not very dilutive, on which it plans to communicate “in the coming days”.
The announcement comes as GenSight anticipates an opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) for Lumevoq, its investigational treatment for Leber hereditary optic neuropathy, in the third quarter of 2023.
This prospect means that a commercial launch could materialize by the end of 2023.
During the first nine months of 2022, the company recorded revenue generated by sales of Lumevoq under a temporary authorization for use granted by the National Agency for the Safety of Medicines (ANSM) in France d an amount of 3.1 million euros.
Listed on the Paris Stock Exchange, the GenSight Biologics share rose by 6.2% on Friday morning following all these announcements.